Zhou Y - Search Results

1

Highly Potent, Selective, Biostable, and Cell-Permeable Cyclic d-Peptide for Dual-Targeting Therapy of Lung Cancer.

Zhou Y, Zou Y, Yang M, Mei S, Liu X, Han H, Zhang CD, Niu MM. Zhou Y, et al. J Am Chem Soc. 2022 Apr 27;144(16):7117-7128. doi: 10.1021/jacs.1c12075. Epub 2022 Apr 13. J Am Chem Soc. 2022. PMID: 35417174

2

Structure-Based Pharmacophore Design and Virtual Screening for Novel Tubulin Inhibitors with Potential Anticancer Activity.

Zhou Y, Di B, Niu MM. Zhou Y, et al. Molecules. 2019 Sep 1;24(17):3181. doi: 10.3390/molecules24173181. Molecules. 2019. PMID: 31480625 Free PMC article.

3

Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors.

Zhou Y, Tang S, Chen T, Niu MM. Zhou Y, et al. Molecules. 2019 Nov 22;24(23):4258. doi: 10.3390/molecules24234258. Molecules. 2019. PMID: 31766720 Free PMC article.

4

Discovery of a Potent PLK1-PBD Small-Molecule Inhibitor as an Anticancer Drug Candidate through Structure-Based Design.

Zhou Y, Yan F, Huo X, Niu MM. Zhou Y, et al. Molecules. 2019 Nov 28;24(23):4351. doi: 10.3390/molecules24234351. Molecules. 2019. PMID: 31795214 Free PMC article.

5

An NRP1/MDM2-Targeted D-Peptide Supramolecular Nanomedicine for High-Efficacy and Low-Toxic Liver Cancer Therapy.

Zhou Y, Chen Y, Tan Y, Hu R, Niu MM. Zhou Y, et al. Adv Healthc Mater. 2021 May;10(9):e2002197. doi: 10.1002/adhm.202002197. Epub 2021 Mar 9. Adv Healthc Mater. 2021. PMID: 33690977

6

A Supramolecular Nanomedicine Based on Bendamustine and MDM2-Targeted D-peptide Inhibitor for Breast Cancer Therapy.

Zhou Y, Chen Y, Huang X, Tan Y, Hu R, Li C, Niu MM. Zhou Y, et al. Adv Healthc Mater. 2021 Nov;10(21):e2100980. doi: 10.1002/adhm.202100980. Epub 2021 Sep 23. Adv Healthc Mater. 2021. PMID: 34558228

7

A GSH/CB Dual-Controlled Self-Assembled Nanomedicine for High-Efficacy Doxorubicin-Resistant Breast Cancer Therapy.

Yang Y, Zhao Q, Peng Z, Zhou Y, Niu MM, Chen L. Yang Y, et al. Among authors: zhou y. Front Pharmacol. 2022 Jan 14;12:811724. doi: 10.3389/fphar.2021.811724. eCollection 2021. Front Pharmacol. 2022. PMID: 35095524 Free PMC article.

8

AIM2 promotes non-small-cell lung cancer cell growth through inflammasome-dependent pathway.

Zhang M, Jin C, Yang Y, Wang K, Zhou Y, Zhou Y, Wang R, Li T, Hu R. Zhang M, et al. Among authors: zhou y. J Cell Physiol. 2019 Nov;234(11):20161-20173. doi: 10.1002/jcp.28617. Epub 2019 Apr 5. J Cell Physiol. 2019. PMID: 30953357

9

Flumethasone enhances the efficacy of chemotherapeutic drugs in lung cancer by inhibiting Nrf2 signaling pathway.

Zhou Y, Zhou Y, Wang K, Li T, Yang M, Wang R, Chen Y, Cao M, Hu R. Zhou Y, et al. Cancer Lett. 2020 Apr 1;474:94-105. doi: 10.1016/j.canlet.2020.01.010. Epub 2020 Jan 16. Cancer Lett. 2020. PMID: 31954771

10

Absent in melanoma 2 suppresses epithelial-mesenchymal transition via Akt and inflammasome pathways in human colorectal cancer cells.

Yang Y, Zhang M, Jin C, Ding Y, Yang M, Wang R, Zhou Y, Zhou Y, Li T, Wang K, Hu R. Yang Y, et al. Among authors: zhou y. J Cell Biochem. 2019 Oct;120(10):17744-17756. doi: 10.1002/jcb.29040. Epub 2019 Jun 18. J Cell Biochem. 2019. PMID: 31210372

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73,267 results

Search Page

Filters